Menu
Search
|

Menu

Close
X

Seattle Genetics Inc SGEN.OQ (NASDAQ Stock Exchange Global Select Market)

66.76 USD
-- (--)
As of Jun 20
chart
Previous Close 66.76
Open --
Volume --
3m Avg Volume 348,545
Today’s High --
Today’s Low --
52 Week High 69.68
52 Week Low 45.31
Shares Outstanding (mil) 158.22
Market Capitalization (mil) 10,408.00
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.29 Mean rating from 14 analysts

KEY STATS

Revenue (mm, USD)
FY18
141
FY17
482
FY16
418
FY15
337
EPS (USD)
FY18
-0.735
FY17
-0.092
FY16
-0.994
FY15
-0.939
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.88
Price to Sales (TTM)
vs sector
20.26
8.30
Price to Book (MRQ)
vs sector
8.25
4.32
Price to Cash Flow (TTM)
vs sector
--
22.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.35
LT Debt to Equity (MRQ)
vs sector
0.00
12.89
Return on Investment (TTM)
vs sector
-6.37
13.21
Return on Equity (TTM)
vs sector
-6.63
15.18

EXECUTIVE LEADERSHIP

Clay Siegall
Chairman of the Board, President, Chief Executive Officer, Since 2004
Salary: $852,354.00
Bonus: $985,000.00
Todd Simpson
Chief Financial Officer, Since 2005
Salary: $475,371.00
Bonus: $269,500.00
Jean Liu
Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary, Since 2014
Salary: $399,829.00
Bonus: $217,681.00
Darren Cline
Executive Vice President - Commercial, Since 2016
Salary: --
Bonus: --
Vaughn Himes
Chief Technical Officer, Since 2016
Salary: $441,138.00
Bonus: $246,900.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

21823 30th Dr SE
BOTHELL   WA   98021-3907

Phone: +1425.5274000

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

SPONSORED STORIES